CelLBxHealth公司将放弃林业发展局对Parsortix的许可证,因为超过97%的单位用于研究,而不是商业销售。 CelLBxHealth will drop its FDA license for Parsortix® as over 97% of units are used for research, not commercial sale.

CelLBxHealth plc 于2026年2月13日宣布,它将停止维持林业发展局Parsortix系统的营业执照和装置清单,理由是超过97%的单位用于内部研究,林业发展局的营业清单没有提供商业利益。 CelLBxHealth plc announced on February 13, 2026, that it will discontinue maintaining its FDA establishment license and device listing for the Parsortix® system, citing that over 97% of units are used for in-house research where FDA listing provides no commercial benefit. 此举旨在提高成本效率,使公司能够将资源转用于收入增长、客户支持和产品开发。 The move, aimed at improving cost efficiency, allows the company to redirect resources toward revenue growth, customer support, and product development. 该决定不影响销售、预测或伙伴关系,CelLBxHealth公司保留随时恢复林业发展局列名的能力。 The decision does not impact sales, forecasts, or partnerships, and CelLBxHealth retains the ability to reinstate the FDA listing at any time. 首席执行官彼得·柯林斯说,这一变化与目前的客户使用量一致,支持精确肿瘤学的长期增长。 CEO Peter Collins said the change aligns with current customer usage and supports long-term growth in precision oncology. 该公司继续在研究、临床试验和实验室开发的测试方面扩大合作。 The company continues expanding collaborations in research, clinical trials, and lab-developed tests.